Two early-phase clinical trials demonstrate the safety and potential clinical utility of stem cell therapies to ease motor ...

In a first-of-its-kind human trial, researchers transplanted iPS-cell-derived dopaminergic progenitors into patients with ...

However, as Parkinson’s disease progresses, levodopa treatment becomes less effective because there are fewer dopamine-releasing (dopaminergic) neurons available to convert levodopa into dopamine.

However, the studies found that cell therapy could replenish dopamine-producing (dopaminergic) neurons in the brain. This provided a potentially more effective treatment with fewer adverse effects.

In a groundbreaking Phase I/II trial conducted at Kyoto University Hospital, researchers have demonstrated the potential of iPS-cell-derived dopaminergic progenitors in treating Parkinson’s disease.

The researchers believe that the stem-cell treatment indeed holds the key to stopping Parkinson's Disease in its tracks, a ...

Human neurons Dopaminergic neurons are the most vulnerable cells in Parkinson's disease. Starting with human stem cells, we generate dopaminergic neurons in a dish. These cells are a handy proxy to ...

Parkinson's disease (PD), the second most common neurodegenerative disorder, is characterized by the loss of dopaminergic neurons in the center of the brain that control movements. These neurons ...

Parkinson’s disease (PD) is a neurodegenerative disease of the central nervous system characterized by the loss of dopaminergic neurons in the substantia nigra and the abnormal aggregation of ...

Artificial neurons organize themselves A research team constructs network of self-learning infomorphic neurons Date: March 28, 2025 Source: Max Planck Institute for Dynamics and Self-Organization ...